JBM  Vol.7 No.1 , January 2019
Level of Fasting C-Peptide as a Predictor of β-Cell Function in Sudanese Patients with Type 2 Diabetes Mellitus
Abstract: Objective: In this study, we assessed the level of fasting C-peptide as a predictor of β-cell function and insulin resistance in patients with Type 2 diabetes mellitus (T2DM), Gezira State-Sudan. Methods: In this cross-sectional study, 100 T2DM patients attending the Diabetic patients care Centre were recruited, thirty five patients were males and sixty five were females, the mean age of the patients was 50.29 ± 0.456 years, and body mass index (BMI) was 26.54 ± 0.437. We estimated β-cell function using fasting C-peptide levels; homeostatic model assessment for β-cell function (HOMA-B) and insulin resistance (HOMA-IR) were calculated from C-peptide and fasting blood glucose (FBG). Results: C-peptide was significantly and positively correlated with HOMA-B and HOMA-IR. FBG also showed significant negative correlation with HOMA-B, but was positively and significantly correlated with HOMA-IR. HbA1c was negatively and significantly correlated with HOMA-B. Patients with low C-peptide levels had increased FBG and HbA1c level, while patients with high C-peptide levels were having high HOMA-IR and HOMA-B. Conclusions: Fasting C-peptide is a useful marker of pancreatic β-cell function, and its circulating levels could be used to evaluate insulin secretion and insulin resistance. Moreover, HOMA-IR is an effective index to achieve glycemic control by appropriate pharmacologic treatment of T2DM.
Cite this paper: Zaki, H. , Abdille, A. and Abdalla, B. (2019) Level of Fasting C-Peptide as a Predictor of β-Cell Function in Sudanese Patients with Type 2 Diabetes Mellitus. Journal of Biosciences and Medicines, 7, 115-123. doi: 10.4236/jbm.2019.71010.

[1]   Nordquist, L., Palm, F. and Andresen, B.T. (2008) Renal and Vascular Benefits of C-Peptide: Molecular Mechanisms of C-Peptide Action. Biologics, 2, 441-452.

[2]   Bloomgarden, Z. (2016) Questioning Glucose Measurements Used in the International Diabetes Federation (Idf) Atlas. Journal of Diabetes, 8, 746-747.

[3]   Zheng, Y., Ley, S.H. and Hu, F.B. (2018) Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and Its Complications. Nature Reviews Endocrinology, 14, 88-98.

[4]   Ashcroft, F.M. and Rorsman, P. (2012) Diabetes Mellitus and the Beta Cell: The Last Ten Years. Cell, 148, 1160-1171.

[5]   American Diabetes Association (2014) Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 37, S81-S90.

[6]   Oran, P.E., Jarvis, J.W., Borges, C.R. and Nelson, R.W. (2010) C-Peptide Micro-heterogeneity in Type 2 Diabetes Populations. Proteomics—Clinical Applications, l 4, 106-111.

[7]   Ghorbani, A. and Shafiee-Nick, R. (2015) Pathological Consequences of C-Peptide Deficiency in Insulin-Dependent Diabetes Mellitus. World Journal of Diabetes, 6, 145-150.

[8]   Polonsky, K.S., Licinio-Paixao, J., Given, B.D., Pugh, W., Rue, P., Galloway, J., Karrison, T. and Frank, B. (1986) Use of Biosynthetic Human C-Peptide in the Measurement of Insulin Secretion Rates in Normal Volunteers and Type I Diabetic Patients. Journal of Clinical Investigation, 77, 98-105.

[9]   Wildova, E., Kraml, P., Potockova, J., Dlouhy, P. and Andel, M. (2017) The Assessment of the Serum C-Peptide and Plasma Glucose Levels by Orally Administered Whey Proteins in Type 2 Diabetes Mellitus. Physiological Research, 66, 993-999.

[10]   Jones, A.G. and Hattersley, A.T. (2013) The Clinical Utility of C-Peptide Measurement in the Care of Patients with Diabetes. Diabetic Medicine, 30, 803-817.

[11]   Marques, R.G., Fontaine, M.J. and Rogers, J. (2004) C-Peptide: Much More Than a Byproduct of Insulin Biosynthesis. Pancreas, 29, 231-238.

[12]   Johansson, B.L, Kernell, A., Sjoberg, S. and Wahren, J. (1993) Influence of Combined C-Peptide and Insulin Administration on Renal Function and Metabolic Control in Diabetes Type 1. The Journal of Clinical Endocrinology & Metabolism, 77, 976-981.

[13]   Zanchi, A., Moczulski, D.K., Hanna, L.S., Wantman, M., Warram, J.H. and Krolewski, A.S. (2000) Risk of Advanced Diabetic Nephropathy in Type 1 Diabetes Is Associated with Endothelial Nitric Oxide Synthase Gene Polymorphism. Kidney International, 57, 405-413.

[14]   Cotter, M.A., Ekberg, K., Wahren, J. and Cameron, N.E. (2003) Effects of Proinsulin C-Peptide in Experimental Diabetic Neuropathy: Vascular Actions and Modulation by Nitric Oxide Synthase Inhibition. Diabetes, 52, 1812-1817.

[15]   Hu, L. and Li, D.H. (2014) Relationship between Modified Homeostasis Model Assessment/Correlative Serum Factors and Diabetic Retinopathy among Type 2 Diabetics with Insulin Therapy in Guangzhou, China. International Journal of Ophthalmology, 7, 463-468.

[16]   Li, X., Zhou, G., Qi, H.Y., Chen, X.Y. and Huang, G. (2004) [Replacement of Insulin by Fasting C-Peptide in Modified Homeostasis Model Assessment to Evaluate Insulin Resistance and Islet Beta Cell Function. Journal of Central South University. Medical Sciences, 29, 419-423.

[17]   Jung, H.S. (2016) Prediction of Diabetes Using Serum C-Peptide. Endocrinology and Metabolism, 31, 275-276.

[18]   Funakoshi, S., Fujimoto, S., Hamasaki, A., Fujiwara, H., Fujita, Y., Ikeda, K., Takahara, S., Seino, Y. and Inagaki, N. (2011) Analysis of Factors Influencing Postprandial C-Peptide Levels in Japanese Patients with Type 2 Diabetes: Comparison with C-Peptide Levels after Glucagon Load. Journal of Diabetes Investigation, 2, 429-434.

[19]   Shimizu, T., Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R. and Zinman, B. (2012) Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Nippon Rinsho, 70, 591-601.

[20]   Fujiwara, D., Takahashi, K., Suzuki, T., Shii, M., Nakashima, Y., Takekawa, S., Yoshida, A. and Matsuoka, T. (2013) Postprandial Serum C-Peptide Value Is the Optimal Index to Identify Patients with Non-Obese Type 2 Diabetes Who Require Multiple Daily Insulin Injection: Analysis of C-Peptide Values before and after Short-Term Intensive Insulin Therapy. Journal of Diabetes Investigation, 4, 618-625.

[21]   Funakoshi, S., Fujimoto, S., Hamasaki, A., Fujiwara, H., Fujita, Y., Ikeda, K., Hamamoto, Y., Hosokawa, M., Seino, Y. and Inagaki, N. (2008) Analysis of Factors Influencing Pancreatic Beta-Cell Function in Japanese Patients with Type 2 Diabetes: Association with Body Mass Index and Duration of Diabetic Exposure. Diabetes Research and Clinical Practice, 82, 353-358.

[22]   Nakayama, H., Kato, T., Nakayama, S., Kaku, H., Muraishi, K., Tokubuchi, I., Hara, K., Kato, T., Wada, N., Tsuruta, M., Ohki, T., Tanaka, K., Mitsuzaki, K., Tajiri, Y. and Yamada, K. (2015) Cross-Sectional and Longitudinal Analyses of Factors Contributing to the Progressive Loss of the Beta-Cell Function in Type 2 Diabetes. Internal Medicine, 54, 1971-1976.

[23]   Fujimoto, K. and Polonsky, K.S. (2009) Pdx1 and Other Factors That Regulate Pancreatic Beta-Cell Survival. Diabetes, Obesity & Metabolism, 11, 30-37.

[24]   Cho, M.J., Kim, M.S., Kim, C.J., Kim, E.Y., Kim, J.D., Kim, E.Y. and Lee, D.Y. (2014) Fasting Serum C-Peptide Is Useful for Initial Classification of Diabetes Mellitus in Children and Adolescents. Annals of Pediatric Endocrinology & Metabolism, 19, 80-85.

[25]   Lee, E.Y., Hwang, S., Lee, S.H., Lee, Y.H., Choi, A.R., Lee, Y., Lee, B.W., Kang, E.S., Ahn, C.W., Cha, B.S. and Lee, H.C. (2014) Post-prandial C-Peptide to Glucose Ratio as a Predictor of Beta-Cell Function and Its Usefulness for Staged Management of Type 2 Diabetes. Journal of Diabetes Investigation, 5, 517-524.

[26]   Meier, J.J., Menge, B.A., Breuer, T.G., Muller, C.A., Tannapfel, A., Uhl, W., Schmidt, W.E. and Schrader, H. (2009) Functional Assessment of Pancreatic Beta-Cell Area in Humans. Diabetes, 58, 1595-1603.